{"preliminary_commentary":{"by_channel":{"x_thread":11},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05549037\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"LungTIME-C01","nct_id":"NCT05549037","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=lungtime-c01-nct05549037. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"LungTIME-C01","arms":[{"description":"All the patients in this arm will be treated with immunochemotherapy before 15:00.","label":"Arm A: Morning group","type":"EXPERIMENTAL"},{"description":"All the patients in this arm will be treated with immunochemotherapy after 15:00.","label":"Arm B: Afternoon group","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-04-30","type":"ACTUAL"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":210,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Pembrolizumab, Sintilimab","otherNames":["time-of-day of administration of immunochemotherapy"],"type":"DRUG"}],"last_update":"2026-06-03","lead_sponsor":"Hunan Province Tumor Hospital","official_title":"Progression Survival Time According to Time-of-Day (ToD) of Administration of Immunochemotherapy for Advanced Non-small Cell Lung Cancer: A Phase III Randomized Control Trial","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2024-12-02","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free survival (PFS)","timeFrame":"Time from first subject dose to study completion, or up to 36 month."}],"references":[{"citation":"Huang Z, Zeng L, Ruan Z, Zeng Q, Yan H, Jiang W, Xiong Y, Zhou C, Yang H, Liu L, Dai J, Zou N, Xu S, Wang Y, Wang Z, Deng J, Chen X, Wang J, Xiang H, Li X, Duchemann B, Chen G, Xia Y, Mok T, Scheiermann C, Levi F, Yang N, Zhang Y. Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial. Nat Med. 2026 Apr;32(4):1233-1240. doi: 10.1038/s41591-025-04181-w. Epub 2026 Feb 2.","pmid":"41629425","type":"DERIVED"}],"start_date":{"date":"2022-09-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC","url":"https://clinicaltrials.gov/study/NCT05549037"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/lungtime-c01-nct05549037"}